Arch Therapeutics (OTCMKTS:ARTH) Given a $3.00 Price Target by HC Wainwright Analysts

HC Wainwright set a $3.00 price target on Arch Therapeutics (OTCMKTS:ARTH) in a research note published on Thursday, March 15th. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other brokerages also recently issued reports on ARTH. Zacks Investment Research raised shares of Arch Therapeutics from a sell rating to a buy rating and set a $0.50 price objective for the company in a research report on Tuesday, February 20th. Ifs Securities downgraded shares of Arch Therapeutics from a strong-buy rating to an outperform rating in a research report on Wednesday, March 14th. Finally, ValuEngine downgraded shares of Arch Therapeutics from a hold rating to a sell rating in a research report on Friday, November 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Arch Therapeutics has an average rating of Hold and a consensus price target of $2.17.

How to Become a New Pot Stock Millionaire

OTCMKTS:ARTH traded up $0.01 during trading hours on Thursday, hitting $0.28. The stock had a trading volume of 172,850 shares, compared to its average volume of 212,942. Arch Therapeutics has a 1-year low of $0.25 and a 1-year high of $0.89.

ILLEGAL ACTIVITY WARNING: “Arch Therapeutics (OTCMKTS:ARTH) Given a $3.00 Price Target by HC Wainwright Analysts” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/07/arch-therapeutics-arth-given-a-3-00-price-target-at-hc-wainwright.html.

About Arch Therapeutics

Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.

Receive News & Ratings for Arch Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply